CinCor Pharma Inc.
| NASDAQ: CINC |
| Healthcare / Biotechnology / USA |
| 20.38 | +1.54 | +8.17% | Vol 356.94K | 1Y Perf - |
| Jul 1st, 2022 16:00 DELAYED |
| BID | 15.57 | ASK | 24.94 | ||
| Open | 18.56 | Previous Close | 18.84 | ||
| Pre-Market | - | After-Market | 20.20 | ||
| - - | -0.18 -0.88% |
| Target Price | 29.00 | Analyst Rating | Strong Buy 1.13 | |
| Potential % | 42.30 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | — - | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 41.79 | Earnings Rating | — | |
| Market Cap | 768.51M | Earnings Date | 9th Aug 2022 | |
| Alpha | -0.12 | Standard Deviation | 0.33 | |
| Beta | -5.45 |
Today's Price Range 18.5622.27 | 52W Range 13.0030.66 |
Summary:
Strong Buy
| Technical Indicators: | Strong Buy |
| Moving Averages: | Strong Buy |
| Performance | |||
|---|---|---|---|
| 1 Week | 7.09% | ||
| 1 Month | 7.49% | ||
| 3 Months | 13.10% | ||
| 6 Months | - | ||
| 1 Year | - | ||
| 3 Years | - | ||
| 5 Years | - | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | - | |||
ROE last 12 Months | -19.45 | |||
ROA (5Y Avg) | - | |||
ROA last 12 Months | -19.10 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -19.47 | |||
Return on invested Capital Q | -13.28 | |||
Return on invested Capital Y | - | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | - |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -10.80 | ||||
| 2.27 | ||||
| - | ||||
| - | ||||
| -16.80 | ||||
| -1.13 | ||||
| 2.27 | ||||
| 8.38 | ||||
| 403.46M | ||||
| Forward PE | - | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 55.30 | ||||
| 56.60 | ||||
| - | ||||
| - | ||||
| - | ||||
| Leverage Ratio | 1.80 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q01 2022 | -0.50 | -0.50 | 0.00 |
| Q04 2021 | -1.56 | -15.71 | -907.05 |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Next Report Date | 9th Aug 2022 |
| Estimated EPS Next Report | -0.50 |
| Estimates Count | 3 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 356.94K |
| Shares Outstanding | 37.71K |
| Shares Float | 19.58M |
| Trades Count | 3.92K |
| Dollar Volume | 7.46M |
| Avg. Volume | 140.14K |
| Avg. Weekly Volume | 166.37K |
| Avg. Monthly Volume | 132.87K |
| Avg. Quarterly Volume | 121.17K |
CinCor Pharma Inc. (NASDAQ: CINC) stock closed at 20.38 per share at the end of the most recent trading day (a 8.17% change compared to the prior day closing price) with a volume of 356.94K shares and market capitalization of 768.51M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 10 people. CinCor Pharma Inc. CEO is Marc de Garidel.
The one-year performance of CinCor Pharma Inc. stock is %, while year-to-date (YTD) performance is %. CINC stock has a five-year performance of %. Its 52-week range is between 13 and 30.66, which gives CINC stock a 52-week price range ratio of 41.79%
CinCor Pharma Inc. currently has a PE ratio of -10.80, a price-to-book (PB) ratio of 2.27, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -19.10%, a ROC of -19.47% and a ROE of -19.45%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from CinCor Pharma Inc., there were 0 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.50 for the next earnings report. CinCor Pharma Inc.’s next earnings report date is 09th Aug 2022.
The consensus rating of Wall Street analysts for CinCor Pharma Inc. is Strong Buy (1.13), with a target price of $29, which is +42.30% compared to the current price. The earnings rating for CinCor Pharma Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
CinCor Pharma Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
CinCor Pharma Inc. has a Strong Buy technical analysis rating based on Technical Indicators (ADX : 25.44, ATR14 : 2.31, CCI20 : 172.49, Chaikin Money Flow : 0.14, MACD : 0.10, Money Flow Index : 76.82, ROC : 40.75, RSI : 57.81, STOCH (14,3) : 78.47, STOCH RSI : 1.00, UO : 52.64, Williams %R : -21.53), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of CinCor Pharma Inc. in the last 12-months were:
CinCor Pharma Inc.
CinCor Pharma Inc is a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases.
CEO: Marc de Garidel
Telephone: +1 844 531-1834
Address: 200 Clarendon Street, Boston 02116, MA, US
Number of employees: 10
TipRanks News for CINC
Thu, 19 May 2022 12:46 GMT Cincor Pharma (CINC) Gets a Buy Rating from Jefferies
- TipRanks. All rights reserved.
